|
| Lanfear Capital's current portfolio
of investments demonstrates our commitment to partner with entrepreneurs
to create value. We are proud of our portfolio companies and
we are pleased with the working relationships that we have developed
with Board members and management teams. |
|
| InteKrin Therapeutics, Inc. |
|
| |
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. |
 |
| |
|
|
|
| |
|
| Saronyx, Inc. |
|
| |
Saronyx Inc., provides decision support and workflow
integration tools for drug development program management. A
bottom-up approach embracing best practices is integrated with
powerful top-down visualization views to provide transparency
and feedback in a true Six-Sigma fashion. Dynamic navigation
provides rapid drill down and analysis into specific information
captured at each organizational level and every process stage.
|
 |
| |
|
|
|
| |
|
| Anthera Pharmaceuticals, Inc. |
|
| |
Anthera Pharmaceuticals is a start-up pharmaceutical
company focused on the in-licensing of promising clinical candidates
for the treatment of serious respiratory and inflammatory diseases.
Anthera has identified four clinical stage products which have
the potential to address a variety of these target diseases
including: Acute Lung Injury, Cystic Fibrosis, COPD, Asthma,
and idiopathic pulmonary fibrosis. |
 |
| |
|
|
|
| |
|
| Coapt Systems, Inc. |
|
| |
Coap Systems Inc. develops bio-absorbable implants
for use in soft tissue fixation during facial cosmetic surgery
procedures. Featuring MultiPoint™ technology, their products
enable physician to reliably place and shape soft tissue without
sutures, pins, or screws. |
 |
| |
|
|
|
| |
| Corthera |
| |
Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera’s lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin. |
 |
| |
|
|
|
| |
|
|
| |
EndoVx |
|
| |
EndoVx's approach has showed effective long term weight loss
in a prior human surgical study. Their proprietary procedure
is quick, bloodless, and done on an out-patient basis. EndoVx
is moving forward to demonstrate the performance of the system
and generate additional clinical data. Lanfear Capital is a
Board Observer of the company. |
EndoVx |
| |
|
|
|
| |
|
|
|
 |
| |
|
|
